BDX vs ISPC · P/E 34, rev $21.84B vs rev $9.3M
Becton Dickinson and Company (BDX) versus iSpecimen Inc (ISPC) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
iSpecimen Inc (ISPC) is a diagnostics & research company listed on US.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported ISPC revenue for 2024-12-31 was $9.3M. Net income was -$12.5M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ISPC currently screens at market cap $4.4M.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. ISPC currently screens at market cap $4.4M.
Not investment advice. Open the BDX and ISPC stock pages for the full models.
Not investment advice.